Dabur India reported an 8% increase in its net profit for the third quarter (Q3) of fiscal year (FY) 2024, to ₹514.2 crore, compared to ₹475.9 crore in the same quarter of the previous year. The company's revenue from operations also grew by 7% to ₹2,878.5 crore in Q3 FY24, from ₹2,689.6 crore in Q3 FY23.
Dabur's Q3 performance was driven by strong volume growth across its key categories, such as Ayurvedic Healthcare, Personal Care, and Home Care. The company's Ayurvedic Healthcare business, which includes brands such as Chyawanprash, Dabur Honitus, and Lakshadi Oil, grew by 9.8% in Q3 FY24. The Personal Care business, which includes brands such as Vatika, Hajmola, and Fem, grew by 6.2% in Q3 FY24. The Home Care business, which includes brands such as Odonil, Exo, and Megaspray, grew by 5.7% in Q3 FY24.
In addition to its strong financial performance, Dabur also announced plans to invest ₹135 crore to set up a new manufacturing facility in south India. This will be the company's first greenfield facility in south India and will help it to meet the growing demand for its products in the region.
Analysts' views on Dabur's Q3 performance
Analysts were generally positive on Dabur's Q3 performance. They noted that the company's volume growth was impressive, particularly in its Ayurvedic Healthcare and Personal Care businesses. They also welcomed the company's decision to invest in a new manufacturing facility in south India.
Overall, Dabur's Q3 results were positive and the company's future prospects look bright. The company's strong brand portfolio, its focus on innovation, and its expansion into new markets are all likely to contribute to its continued growth in the coming years.
